Rigel Pharmaceuticals | RIGL - Selling And Administration Expenses


Rigel Pharmaceuticals reported $27.04M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Agenus USD 6.21M 4.34M Mar/2026
Amgen USD 1.72B 134M Jun/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Celldex Therapeutics USD 13.1M 1.65M Jun/2026
Daiichi Sankyo JPY 249.96B 21.73B Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Halozyme Therapeutics USD 57M 10.71M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Intrexon USD 10.31M 41K Jun/2024
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Ligand Pharmaceuticals USD 29.12M 8.29M Jun/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Veracyte USD 55.71M 4.87M Jun/2026